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Since the publication of the National Lung Screening Trial in 2011 demonstrating a 
20% reduction in lung cancer specific mortality by annual low-dose CT (LDCT) [1], 
implementation of screening has continued apace in the United States. Other 
developed nations, perhaps mindful of the potential cost implications of national 
screening programmes, have been more reticent, with many awaiting the final 
outcome data from the largest European randomised trial - the Dutch-Belgian 
NELSON study which remains in follow-up [2].  
 
Despite the convincing mortality reduction in NLST, questions remain about 
implementation of LDCT screening for lung cancer. Unresolved issues include how to 
best identify high risk individuals for screening, what is the most appropriate screening 
interval to achieve an optimal balance between mortality reduction and cost-
effectiveness, and how to minimise possible harms associated with screening - 
particularly overdiagnosis. This issue of Thorax includes two papers which provide 
important additions to accumulating evidence in this field.  
 
Paci and colleagues [3] report lung cancer incidence and mortality rates from the 
ITALUNG randomised lung cancer screening trial conducted in Tuscany, Italy 
commencing in 2004. From an invited population of over 71,232 subjects aged 55-69 
years, 1,613 were randomised to four rounds of annual LDCT screening and 1,593 to 
usual care. Like many of the other European screening studies, ITALUNG was not 
powered to demonstrate mortality reduction in isolation, and pooled analysis with other 
similarly designed randomised trials is planned.  
 
As expected, lung cancer incidence was higher in the intervention group during the 
four year screening period (55% excess diagnoses vs usual care group). However, 
this was followed by a compensatory reduction in diagnoses during the 5 year follow-
up period, such that there was no significant difference in incidence rates between the 
groups at the end of the study. After a median follow-up of 9 years, the authors report 
non-significant reductions of 17% for overall mortality (RR=0.83, 95% CI 0.67-1.03), 
and 30% for lung cancer specific mortality (RR=0.70, 95% CI 0.47-1.03).  
 
The completion of “catch-up” in lung cancer diagnoses in the non-screened arm is an 
important finding as it would tend to suggest that there was no significant 
overdiagnosis from LDCT screening. This is in contrast to the NLST, where there was 
an 13% excess in diagnoses in the LDCT arm compared to the CXR arm [1], with a 
probability of 18.5% that any CT screen-detected cancer was overdiagnosed [4]. This 
may relate to the shorter follow-up period in NLST (6.5 years compared to 9 years in 
ITALUNG), and it maybe that with longer follow-up, catch-up will be seen in the NLST 
study also. Alternatively, this may reflect different management strategies for screen-
detected nodules - particularly indolent adenocarcinomas manifesting as pure ground 
glass nodules (pGGNs). Analysis of possible overdiagnosis by histological subtype in 
NLST showed that up to 78.9% of the (then-termed) bronchio-alveolar lung cancers 
detected by LDCT were overdiagnosed [4]. The International Early Lung Cancer 
Action Programme group have demonstrated the safety of continued annual 
observation for pGGNs in the absence of a solid component [5]. Neither NLST nor 
ITALUNG have published nodule management protocols, so it is impossible to assess 
the extent to which management differed between these studies. Nevertheless, there 
is increasing evidence suggesting that these indolent lesions maybe best observed 
rather than removed, and future screening studies should consider prospective 
evaluation of protocols mandating observation only for pGGNs to minimise 
overdiagnosis.  
 
The larger reductions in lung cancer specific mortality and all-cause mortality in 
ITALUNG (17% and 30% respectively) compared to NLST (6.7% and 20% 
respectively) are discussed by the authors. Possible explanations proposed are the 
longer follow-up period, and the more advanced stage distribution of lung cancers in 
the control arm of ITALUNG compared to NLST. Caution must be exercised in 
assessing non-significant outcomes for which the study was not originally powered. 
However, the stage distribution in the non-CT screened arms are very different 
between the two studies. In the usual care arm of ITALUNG (which did not receive 
CXR screening), only 11% of patients diagnosed with lung cancer had stage I disease 
compared to 31% in the CXR screened control arm of NLST. The low proportion of 
usual care patients with stage I disease in Italy reflects data from other European 
countries published in the International Cancer Benchmarking Partnership (Stage I 
disease 14.0% in Denmark, 13.5% in UK)[6]. It maybe therefore that mortality 
reduction from LDCT screening maybe augmented in locations with more adverse 
stage distribution in their background populations, or indeed more simply, in 
populations not screened with CXRs. The final results of the NELSON trial are 
therefore keenly awaited in this context. Interestingly, the proportion of patients with 
stage I disease in the usual care (unscreened) arm of the Prostate Lung Colorectal 
and Ovarian study of CXR screening for lung cancer was also high at 27% [7].  
 
The issue of optimal screening interval is addressed by Yousaf-Khan and colleagues 
from the NELSON group [8]. Unlike NLST, the NELSON study employed a volumetric-
based nodule management protocol, and included increasing screening intervals (of 
1, then 2 then 2.5 years) during the course of the study. The data presented here 
shows the cancer yield of the fourth screening round (performed 2.5 years after the 
third) according to the results of previous screening rounds and patient characteristics. 
Outcomes from screening rounds were classed as negative (newly detected nodules 
<50mm3 or previously detected nodules with volume doubling time of >600 days), 
indeterminate (newly detected nodules 50-500mm3 or VDT of 400-600 days) or 
positive (newly detected nodule >500mm3 or VDT <400 days).  
 
Of the 5,279 participants in the fourth screening round, 3,856 had all negative previous 
rounds, 1,342 had had at least one indeterminate previous round (but never a positive) 
and 81 had a previous positive round. The proportion of these groups with a screen-
detected cancer at the fourth round were 0.6% for those with all previous negatives 
and 1.6% for those with at least one previous indeterminate result equating to an odds 
ratio of 2.7 (95% CI 1.5-5.1 vs negative result). No clinical factors (age, gender, starting 
age of smoking, smoking status or pack-years smoked) significantly predicted 
detection of lung cancer in the fourth round. 
 
The low cancer yield following a previous negative round described by the NELSON 
group matches closely with a similar recent retrospective analysis of NLST [9]. Of 
19,066 participants with a negative prevalence scan (first scan), the yield of lung 
cancer at the first incidence screen (after a one year interval) was only 0.34%. 
Considering the associated harms of overly frequent screening, the authors suggest 
that increasing the screening interval maybe appropriate for those with negative 
baseline scans.  
 
Extending screening intervals however, risks lowering the rate of detection of early 
stage cancers. Importantly another recent Thorax publication from the NELSON group 
demonstrated a progressive reduction in the proportion of screen-detected cancers at 
the earliest stage (Stage IA - TNM 7th edition) with increasing screening interval 
(74.1% following 1 year interval, 64.9% following 2 year interval, 47.8% following 2.5 
year interval) [10]. The survival advantage of diagnosing lung cancer at its earliest 
(and smallest) stage is highlighted in the 8th edition of TNM classification by the IASLC 
lung cancer staging project. Five year survival rates for Stage IA1 (tumour ≤1cm), 
Stage IA2 (tumour 1-2cm) and Stage IA3 (tumour 2-3cm) were 92%, 83% and 77% 
respectively [11]. The demonstrated reduction in earliest stage disease with increased 
screening interval may therefore attenuate the benefits demonstrated in NLST.  
 
The combined data from NELSON and NLST therefore suggest that one size may not 
fit all when selecting a screening interval. A 2.5 year (or even 2 year interval) seems 
to be associated with a trend to more advanced disease, and therefore may not be 
appropriate for all participants as it risks losing some of the mortality reduction 
originally described. However the very low cancer yield following previous negative 
rounds may identify a low-risk group where a prolonged interval maybe safe. Those 
with a previous indeterminate result (even where the nodule in question is 
subsequently deemed benign) may benefit from ongoing annual screens due to the 
increased risk that the indeterminate result seems to confer. Tailoring screening 
interval to lung cancer risk (by virtue of screening history) is therefore one promising 
option to optimise the benefits of screening whilst minimising costs and harms. Future 
studies should therefore look to prospectively evaluate such tailored screening 
intervals.  
 
A final and intriguing question is why indeterminate nodules, subsequently deemed 
benign by further evaluation, still seem to confer an increased risk of lung cancer. 
Some of this may reflect the original NELSON nodule management protocol. In the 
protocol first described [12], all nodules less than 50mm3 were deemed benign and 
ignored. However, subsequent analysis from NELSON suggests that this threshold 
maybe too high when considering newly appearing nodules. Instead Walter and 
colleagues propose a lower volume cut-off of 27mm3 suggesting that nodules ignored 
according to the protocol at the time may have conferred increased risk. However, the 
majority of lung cancers diagnosed in round 4 in the current study were detected in a 
new nodule not previously seen. Why then should benign nodules (many of which 
subsequently disappear) predict the development of cancer. Do these nodules reflect 
alveolar inflammation either in direct response to cigarette smoke, or to intercurrent 
infection commonly seen in patients with COPD, and this in turn predisposes to lung 
cancer? Or could the nodules that appear and disappear in fact be early cancers 
subsequently cleared by immune-editing mechanisms? In an age when the funders of 
healthcare are increasingly concerned about how to resource the anticipated 
explosion in immuno-oncology, are we witnessing this phenomenon for free in serial 
CT screening scans? 
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